Predicting onset of symptomatic Alzheimerʼs disease with plasma p-tau217 clocks
Kellen K. Petersen / nature - Nature Medicine, Published online: 19 February 2026; doi:10.1038/s41591-026-04206-yPlasma p-tau217 tests used to develop clocks that predict when cognitively unimpaired individuals would develop symptoms of Alzheimerʼs disease.
AI Summary: A Nature Medicine study presents plasma p‑tau217 “clocks” that estimate when symptomatic Alzheimer’s disease is likely to begin, offering a blood-based forecast years before cognitive decline appears. The test could reshape trial enrollment, early intervention timing and patient counseling—validation and access hurdles remain, but at least worried boomers get a calendar to dread.
Related Stories
Researchers report extracorporeal cross‑circulation using genetically modified pig livers / 4 months
FDA Lifts Hold on Intellia’s Phase 3 Gene Editing Trial / 5 months
FDA rejects Corcept’s cortisol modulator triggering setback / 6 months
FDA approves Rucaparib for advanced prostate cancer / 6 months
FDA approves first gene therapy for Wiskott‐Aldrich syndrome / 6 months
FDA Approves Novartis’ Itvisma Gene Therapy for SMA Across Age Groups / 7 months
FDA Approves Ziftomenib for AML Treatment / 7 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Hospital Operations, Medical Devices, Medicaid, Drug Pricing and look for the RSS link.
StackHealth Time Machine